Long-term effects of tetrabenazine in hyperkinetic movement disorders

Neurology

Volumn 48, Issue 2, 1997, Pages 358-362

  Jankovic, Joseph ^a   Beach, Jennifer ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; TETRABENAZINE;

ADULT; AKATHISIA; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOPAMINE RECEPTOR BLOCKING; DROWSINESS; DRUG EFFICACY; DYSTONIA; FEMALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; PARKINSONISM; PRIORITY JOURNAL; STEREOTYPY;

EID: 0031029072     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.2.358     Document Type: Article

References (51)

1. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
2. Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine-decreasing drugs with psychotropic action. Int Rev Neurobiol 1962;4:275-306.
3. Carlsson A. Monoamine-depleting drugs. Pharmacol Ther 1975;1:394-400.
4. Lane JD, Smith JE, Shea PA, McBride WJ. Neurochemical changes following the administration of depleters of biogenic monoamine. Life Sci 1976;19:1663-1667.
5. Kuczenski R. Differential effects of reserpine and tetrabenazine on rat striatal synaptosomal dopamine biosynthesis and synaptosomal dopamine pools. J Pharmacol Exp Ther 1977; 201:357-367.
6. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-719.
7. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12: 257-262.
8. Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in the rat brain. J Pharmacol Exp Ther 1983;225:515-521.
9. Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202.
10. Kilbourn MR, DaSilva JN, Frey KA, Koeppe RA, Kuhl DE. In vivo imaging of vesicular monoamine transporters in human brain using tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318.
11. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 1983;7:276-279.
12. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;37:227-289.
13. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394.
14. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47.
15. Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972;35:186-191.
16. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-1054.
17. Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 1988;33:11-13.
18. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis 1993;181:649-651.
19. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993; 43:937-941.
20. Kazamatsuri H, Chein C-P, Cole J. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;1304:479-483.
21. Lang AE, Marsden CD. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982; 5:375-387.
22. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: lateonset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
23. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Movement Disorders 1986;1:193-208.
24. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-175.
25. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53-57.
26. Pakkenberg H, Fog R. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both. Arch Neurol 1974;31:352-353.
27. Bartels M, Zeller E. Tetrabenazine (Nitornan) therapy of chronic spontaneous oral dyskinesia: a video- and EMG-controlled study. Eur Arch Psychiatry Neurol Sci 1984;234: 172-174.
28. Fog R, Pakkenberg H. Combined Nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta Neurol Scand 1970;46:249-251.
29. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1:104-107.
30. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976;1: 583-584.
31. Hawkes CH, Nourse CH. Tetrabenazine in Sydenham's chorea. Br Med J 1977;1:1391-1392.
32. Toglia JU, McGlamery M, Sambandham RR. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. J Clin Psychiatry 1978;39:81-87.
33. Godwin-Austen RB. The treatment of the choreas and athetotic dystonias. J R Coll Physicians Lond 1979;13:35-38.
34. Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol 1988;23:466-469.
35. Giménez-Roldán S, Mateo D. Huntington's disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-287.
36. Sweet RD, Brun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome: effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 1974;31:857-861.
37. Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-692.
38. Heggarty H, Wright T. Tetrabenazine in athetoid cerebral palsy. Dev Med Child Neurol 1974;16:137-142.
39. Pearce J. Reversal of hemiballismus by tetrabenazine. JAMA 1972;219:1345.
40. Martí-Massó JF, Obeso JA. Coprolalia associated with hemiballismus: response to tetrabenazine. Clin Neuropharmacol 1985;8:189-190.
41. Dewey RB, Jankovic J. Hemiballism-hemichorea: clinical and pharmacologie findings in 21 patients. Arch Neurol 1989;46: 862-867.
42. Jankovic J, Pardo R. Segmental myoclonus: clinical and pharmacologic study. Arch Neurol 1986;43:1025-1031.
43. Furukawa T, Ushizima I, Ono N. Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacologia 1975;42:243-248.
44. Reches A, Hassan MN, Jackson VR, Fahn S. Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine. Life Sci 1983;33: 157-160.
45. Chou JCY. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991;11:3-21.
46. Mikkelsen BO. Tolerance of tetrabenazine during long-term treatment. Acta Neurol Scand 1983;68:57-60.
47. Calne DB, Webster RA. Tremor induced by tetrabenazine. Br J Pharmacol 1969;37:468-475.
48. Mateo D, Muñoz-Blanco JL, Giménez-Roldán S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-68.
49. Ossemann M, Sindic CJM, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996; 11:95.
50. Fitzgerald PM, Jankovic J. Tardive oculogyric crises. Neurology 1989;39:1334-1437.
51. Jankovic J, Stone L. Dystonic tics in patients with Tourette's syndrome. Mov Disord 1991;6:248-252.